Drug Profile
Research programme: dexamethasone ophthalmic - Novagali Pharma
Alternative Names: Nova 22026Latest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Novagali Pharma
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ocular inflammation
Most Recent Events
- 22 Jan 2008 Discontinued - Preclinical for Ocular inflammation in France (Ophthalmic)
- 25 Oct 2006 Preclinical trials in Ocular inflammation in France (Ophthalmic)